AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Phase 1 randomized, double-blind, three period, crossover study comparing the
pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid
insulin aspart (AT247), NovoLog® and Fiasp® in participants with type 1 diabetes mellitus
(T1DM) during continuous subcutaneous infusion (CSII)